Maria Del Carmen Nadal Massanet’s Post

Bridge Bio Eidosibute ( AG10) in phase III for ATTRcm is a new opction for ouers Amilos whith transtirretin. #Acoramidis #ATTRCM #PhaseIII #SOMOSAMILO www.amilo.es

View organization page for BridgeBio, graphic

43,543 followers

Our transthyretin amyloidosis (ATTR) team is heading to ESC Heart Failure hosted by European Society of Cardiology! This year, we will be sharing updates from our ATTRibute-CM Phase 3 trial in one oral presentation and three moderated poster presentations. We will also be supporting a Satellite Symposium with leading physicians in the cardiology space. Check out our website to learn about our latest news: bridgebio.com/what-is-attr 

To view or add a comment, sign in

Explore topics